HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Carcinosarcoma-induced endothelial cells tube formation through KDR/Flk-1 is blocked by TNP-470.

Abstract
We evaluated the usefulness of TNP-470 as an anti-cancer agent on a human uterine carcinosarcoma cell line (FU-MMT-1). FU-MMT-1 induced human arterial endothelial cell (HAEC) tube formation on an in vitro co-cultured model of FU-MMT-1 and HAECs on a matrix gel, and was blocked by vascular endothelial growth factor (VEGF)-2 receptor (KDR/Flk-1) tyrosine kinase inhibitor. Lower concentration of TNP-470 inhibited the tube formation. Cell proliferation of FU-MMT-1 but not HAEC was inhibited by lower concentration of TNP-470. In addition, lower concentration of TNP-470 blocked VEGF production on FU-MMT-1. Our results suggest that TNP-470 directly inhibited FU-MMT-1 but not HAEC growth accompanied with the inhibition of VEGF production, subsequently induced anti-angiogenesis on HAEC.
AuthorsShin-ichiro Miura, Makoto Emoto, Yoshino Matsuo, Tatsuhiko Kawarabayashi, Keijiro Saku
JournalCancer letters (Cancer Lett) Vol. 203 Issue 1 Pg. 45-50 (Jan 08 2004) ISSN: 0304-3835 [Print] Ireland
PMID14670616 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Angiogenesis Inhibitors
  • Cyclohexanes
  • Sesquiterpenes
  • Vascular Endothelial Growth Factor Receptor-2
  • Matrix Metalloproteinase 2
  • Matrix Metalloproteinase 9
  • O-(Chloroacetylcarbamoyl)fumagillol
Topics
  • Angiogenesis Inhibitors (pharmacology)
  • Carcinosarcoma (pathology)
  • Cell Division (drug effects)
  • Cyclohexanes
  • Endothelium, Vascular (drug effects)
  • Female
  • Humans
  • Matrix Metalloproteinase 2 (metabolism)
  • Matrix Metalloproteinase 9 (metabolism)
  • Neovascularization, Pathologic (prevention & control)
  • O-(Chloroacetylcarbamoyl)fumagillol
  • Sesquiterpenes (pharmacology)
  • Tumor Cells, Cultured
  • Vascular Endothelial Growth Factor Receptor-2 (antagonists & inhibitors)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: